Covaxin gets WHO’s emergency use nod

Covaxin gets WHO’s emergency use nod

Science & Tech

  • India’s first indigenous COVID-19 vaccine, Bharat Biotech’s Covaxin, was granted Emergency Use Listing (EUL) by the World Health Organization (WHO).
  • It has been granted EUL for use in persons 18 years and above, over two doses spaced four weeks apart.
  • However, no recommendation has been made for use in children, and available data for use on pregnant women is insufficient to assess safety or efficacy, the WHO said.

About Covaxin

  • Covaxin is a whole virion-inactivated vaccine against SARS-CoV-2, developed in partnership with the Indian Council of Medical Research and the National Institute of Virology,

How WHO’s nod will be helpful?

  • The EUL is a prerequisite for the COVAX initiative in vaccine supply, and allows countries to expedite their own regulatory approval to import and administer COVID-19 vaccines.
  • The move is expected to ease international travel for Indians who have opted for the vaccine but experts say that this would be subjected to countries clearing Covaxin through their regulatory processes.
  • According to  WHO, Covaxin was found to have 78% efficacy against COVID-19 of any severity, 14 or more days after the second dose.
  • WHO also said it is extremely suitable for low- and middle-income countries due to its easy storage requirements.
  •  

Source : The Hindu